BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 1,357 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 1,357 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $266.76, for a total value of $361,993.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaobin Wu also recently made the following trade(s):

• On Thursday, June 11th, Xiaobin Wu sold 626 shares of BeOne Medicines stock. The stock was sold at an average price of $261.20, for a total value of $163,511.20.
• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The shares were sold at an average price of $269.37, for a total transaction of $399,745.08.

BeOne Medicines Trading Up 2.8%

NASDAQ ONC opened at $270.15 on Friday. The company’s 50-day moving average price is $296.16 and its 200-day moving average price is $312.45. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The stock has a market cap of $29.64 billion, a PE ratio of 60.44 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $239.25 and a 12 month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The company had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Institutional Investors Weigh In On BeOne Medicines

Institutional investors have recently bought and sold shares of the company. EFG International AG acquired a new position in shares of BeOne Medicines during the fourth quarter worth $25,000. Leonteq Securities AG acquired a new stake in shares of BeOne Medicines in the 4th quarter worth $35,000. Daiwa Securities Group Inc. purchased a new position in BeOne Medicines during the 2nd quarter worth $35,000. CWM LLC grew its stake in BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the last quarter. Finally, Group One Trading LLC purchased a new position in BeOne Medicines during the 4th quarter worth $61,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ONC. Royal Bank Of Canada boosted their price target on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Wells Fargo & Company assumed coverage on BeOne Medicines in a report on Monday, May 4th. They set an “overweight” rating and a $400.00 price objective on the stock. Truist Financial reaffirmed a “buy” rating and set a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Finally, Barclays upped their target price on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.